

STRENGTHENING COOPERATION ON HEALTH TECHNOLOGY ASSESSMENT

WHAT IS HTA?



Is this medicine a better treatment for a certain disease?



Will this new scanner really lead to a better diagnosis?



Does this innovative surgery improve the patient's treatment?

HEALTH TECHNOLOGY ASSESSMENT:

procedure for assessing the **added value of new medicines and medical devices**

- PROPOSAL FOR A NEW REGULATION -

WHAT'S NEW?



Common European assessment methods

Shared data and expertise

Common procedures across the EU

WHAT ARE THE BENEFITS

Higher level of **human health protection**

Faster market access for **innovative products**

More **transparency** for patients and producers

No more **duplication** of work for health authorities and industry



AREAS OF HTA COOPERATION



Joint clinical assessments

Scientific consultations on the development of new products

Mapping of emerging health technologies

Voluntary cooperation on other areas (e.g. surgical procedures)

NEW MEDICINES



NEW MEDICAL DEVICES

High-risk devices with high impact on patients, public health and EU health systems

EU ASSESSMENT
(jointly done by the Member States)

NATIONAL ASSESSMENT

CLINICAL ASSESSMENT
(benefits compared to existing treatments)

NON-CLINICAL ASSESSMENT
(economic, social and ethical aspects)

CLINICAL ASSESSMENT
(benefits compared to existing treatments)

NON-CLINICAL ASSESSMENT
(economic, social and ethical aspects)

National decisions on pricing and reimbursement

TIMELINE

31 JANUARY 2018

2019

+3 YEARS

+ 3 YEARS

ADOPTION OF THE COMMISSION PROPOSAL

ADOPTION BY THE PARLIAMENT AND THE COUNCIL

START OF APPLICATION OF THE EU REGULATION

END OF THE TRANSITIONAL PERIOD FOR EU MEMBER STATES